100% Healing Rate at 8 Weeks, 93.8% at 4 Weeks

Onconic Therapeutics announced on January 23 that the results of a Phase 3 clinical trial of the gastric acid secretion inhibitor (P-CAB) Zacuvo (ingredient name: Zastaprazan) in patients with gastric ulcers have been published in the international journal 'Gut and Liver'.

Onconic Therapeutics logo image. Onconic Therapeutics

Onconic Therapeutics logo image. Onconic Therapeutics

View original image

This study was a randomized, double-blind clinical trial conducted at 39 medical institutions in Korea, involving 329 patients with gastric ulcers. The efficacy and safety of administering 20 mg of Zacuvo for up to eight weeks were evaluated.


The study found that after eight weeks of treatment, endoscopic ulcer healing was confirmed in all patients in the Zacuvo group. The healing rate at week four was 93.84%.


The size of the ulcers also showed a significant reduction compared to before treatment. The average ulcer size decreased to less than 1 mm after four weeks of administration. By the eighth week, ulcers were no longer observed in most patients.


The researchers concluded in the paper that Zacuvo demonstrated a high healing rate and a clinically acceptable safety profile in patients with gastric ulcers.


Zacuvo obtained approval for the gastric ulcer treatment indication last year and is currently covered by insurance prescriptions. Based on these study results, Onconic Therapeutics is also conducting a Phase 3 clinical trial targeting non-erosive gastroesophageal reflux disease and the prevention of NSAID-induced ulcers.



A representative from Onconic Therapeutics stated, "We have reconfirmed the clinical efficacy and safety of gastric ulcer treatment through a large-scale clinical trial," adding, "We plan to expand the application of Zacuvo to a broader range of acid-related diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing